

Virtual meeting



Mumbai Hematology Group

CLL Colloquium

Best of **EHA & ASCO**

in the field of CLL management

Friday, 1st July 2022

7.15 pm IST

Supported by

AstraZeneca 



Pharmafer

Scientific Agenda

7.15 pm	Welcome & Introduction	Dr. M. B. Agarwal, Mumbai
7.15 pm – 7.25 pm	Importance of cytogenetics and prognostic marker testing in CLL	Dr. Srinidhi Nathany, RGCI, New Delhi
7.30 pm – 7.55 pm	CLL with comorbidities: How to treat?	Dr. Chirag Shah, Ahmedabad
8.00 pm – 8.25 pm	How do I manage CLL using novel targeted agents in combination? (An update from EHA & ASCO)	Dr. Wojciech Jurczak, Poland
8.30 pm – 8.50 pm	Debate High risk CLL: Treat until progression Moderator: Dr. M. B. Agarwal, Mumbai	In favor Dr Rahul Naithani, New Delhi Against Dr. Satish Kumar A, Bengaluru
8.55 pm – 9.15 pm	Q & A session Moderator: Dr. M. B. Agarwal, Mumbai	Participants: All the guest speakers as above Dr. Amrita Ramaswami, Gurugram Dr. Harshit Khurana, Pune Dr. Mobin Paul, Kochi Dr. Rayaz Ahmed, New Delhi Dr. Sandip Shah, Ahmedabad Dr. Stalin Chowdary Bala, Hyderabad Dr. Sumeet Mirgh, Mumbai Dr. Tuphan Dolai, Kolkata
9.15 pm	Vote of Thanks & Closing Remarks	AstraZeneca

Faculty



Dr. Shrinidhi Nathany

Attending consultant
Molecular Diagnostics Section
Department of Pathology
Rajiv Gandhi Cancer Institute and Research Center
New Delhi



Dr. Chirag Shah

Director
Dept of Hematology, Oncology, Stem Cell Transplant
Apollo Hospitals International Ltd.
Ahmedabad



Prof. Wojciech Jurczak, MD, PhD

Consultant and professor of hematology
Memorial Maria Skłodowska Curie
National Research Institute of Oncology
Cracow, Poland



Dr. M B Agarwal

Prof & Head
Dept of Hematology
Bombay Hospital Institute of Medical Sciences, Mumbai
Consultant Hematologist
Lilavati Hospital & Breach Candy Hospital, Mumbai

Faculty



Dr Rahul Naithani

Director-Hematology & Bone Marrow Transplant
Max Superspeciality Hospital, Saket
New Delhi



Dr Satishkumar A

Hematologist & Hemato-oncologist
Manipal Hospital
Yashwanthpur
Bengaluru



Dr. Amrita Ramaswami

MD, DM (Clin. Hematology)
Medical & Hemato-Oncologist
Associate consultant
Medanta-The Medicity
Gurugram



Group Captain (Dr.) Harshit Khurana

Senior Advisor (Medicine),
Clinical Hematologist & BMT Physician
Command Hospital (Southern Command)
Pune

Faculty



Dr. Mobin Paul

Consultant - Clinical Hematology and Oncology
Dept of Clinical Hematology & Hemato-Oncology
Rajagiri Hospital
Kochi



Dr Rayaz Ahmed

Sr. Consultant
Haemato Oncology & bone marrow transplant
Department of Hematology
Rajiv Gandhi Cancer Institute & Research Centre, Rohini
New Delhi



Dr. Sandip Shah


Consultant Hemato-oncologist & Bone Marrow Transplanter
In Charge, BMT Department
Dept of Medical Oncology
Gujarat Cancer Research Institute
Hemato Oncology Clinic
Vedanta Institute of Medical Sciences, Ahmedabad



Dr. Stalin Chowdary Bala

MD DM DNB MRCP (Med Onc)
Associate Professor
Department of Medical Oncology
Nizam's Institute of Medical Sciences
Punjagutta, Hyderabad

Faculty



Dr Sumeet P Mirgh

Assistant Professor
Adult Hematolymphoid & BMT
Tata Memorial Centre & ACTREC
Mumbai



Dr. Tuphan Kanti Dolai

Professor & Head
Hematology Department
NRS Medical College and Hospital
Kolkata

Our International Guest Speaker

Prof. Wojciech Jurczak, MD, PhD

Consultant and professor of hematology

Memorial Maria Skłodowska Curie National Research Institute of Oncology
Cracow, Poland



- Dr. Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.
- Most of his research activity in the first 15 years was related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation.
- At that time radio-immunotherapy with Yttrium-90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in monotherapy or as an element of Z-BEAM conditioned ASCT.
- During the last decade in Hematology, numerous drugs, with an alternative mechanism of action to classical cytostatics were developed.
- At Jagiellonian University, he has led & participated in over 70 clinical trials, including phase 1-3 followed by expansion cohorts.
- He is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars.
- At present, his research is focused on developing 2nd generation BTK inhibitors, anti-PD1 molecules, DARTs and BITEs.
- He is a member of numerous scientific societies (ASH, ASCO, PLRG, EMCLN and ICOS) and consultant for EMA (European Medicines Agency).
- His research papers have been published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc. Cumulative IF > 650, H-index – 20 and citations > 3000.

Best of **CLL Colloquium**
EHA & ASCO in the field of CLL management
Friday, 1st July 2022

Register Now!

Click on below link to register:

<https://forms.gle/1aGfZbdHf31hdDWt9>

All registered delegates will receive the attendee joining link on your registered email id. You may also visit our website www.mhgindia.com

Please send your queries related to the webinar on kalpesh@perfectsquare.co.in.



Mumbai Hematology Group

Hematology Centre, Ghamat Lodge,
804-A, Dr. B. Ambedkar Road, Dadar TT, Mumbai 400014.
Email ID: mbagarwal1@gmail.com

Event Partner

